299 related articles for article (PubMed ID: 28654150)
1. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report.
Thorlacius L; Theut Riis P; Jemec GBE
Br J Dermatol; 2018 Jul; 179(1):182-185. PubMed ID: 28654150
[TBL] [Abstract][Full Text] [Related]
2. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.
Schuch A; Fischer T; Boehner A; Biedermann T; Volz T
Acta Derm Venereol; 2018 Jan; 98(1):151-152. PubMed ID: 28902952
[No Abstract] [Full Text] [Related]
3. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.
Stergianou D; Kanni T; Damoulari C; Giamarellos-Bourboulis EJ
Expert Opin Biol Ther; 2024 Apr; 24(4):225-232. PubMed ID: 38602836
[TBL] [Abstract][Full Text] [Related]
4. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
5. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.
Prussick L; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Abdat R; Alomran A; Zancanaro P; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
Br J Dermatol; 2019 Sep; 181(3):609-611. PubMed ID: 30801662
[No Abstract] [Full Text] [Related]
6. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
7. Novel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report.
Gutierrez E; Issa N; Resnik B
J Drugs Dermatol; 2022 Dec; 21(12):1358-1360. PubMed ID: 36468954
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
Gottlieb A; Natsis NE; Kerdel F; Forman S; Gonzalez E; Jimenez G; Hernandez L; Kaffenberger J; Guido G; Lucas K; Montes D; Gold M; Babcock C; Simard J
J Invest Dermatol; 2020 Aug; 140(8):1538-1545.e2. PubMed ID: 32004568
[TBL] [Abstract][Full Text] [Related]
9. Successful control of hidradenitis suppurativa with verapamil: a case report.
Laroche ML; Teste M; Vanoost J; Geniaux H
Fundam Clin Pharmacol; 2019 Feb; 33(1):122-124. PubMed ID: 30025186
[TBL] [Abstract][Full Text] [Related]
10. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
Yen CF; Huang YH; Chi CC
Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
[TBL] [Abstract][Full Text] [Related]
11. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
12. Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa.
Giuffrida R; Cannavò SP; Coppola M; Guarneri C
Curr Pharm Biotechnol; 2021; 22(1):59-72. PubMed ID: 32368973
[TBL] [Abstract][Full Text] [Related]
13. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab.
Groleau PF; Grossberg AL; Gaspari AA
Cutis; 2015 Jun; 95(6):337-42. PubMed ID: 26125210
[TBL] [Abstract][Full Text] [Related]
14. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
Gulliver WP; Jemec GB; Baker KA
J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
[TBL] [Abstract][Full Text] [Related]
15. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
16. A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma.
Scheinfeld N
Dermatol Online J; 2014 Mar; 20(3):. PubMed ID: 24656278
[TBL] [Abstract][Full Text] [Related]
17. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
[TBL] [Abstract][Full Text] [Related]
18. Pain in Hidradenitis Suppurativa: A Pilot Study.
Ring HC; Sørensen H; Miller IM; List EK; Saunte DM; Jemec GB
Acta Derm Venereol; 2016 May; 96(4):554-6. PubMed ID: 26631388
[No Abstract] [Full Text] [Related]
19. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa.
Yao Y; Thomsen SF
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469692
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab in the treatment of hidradenitis suppurativa.
Snyder CL; Gibson RS; Porter ML; Kimball AB
Immunotherapy; 2023 Dec; 15(17):1449-1457. PubMed ID: 37840286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
